Respiratory AcidosisMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

702 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp51

Immediate priorities

›Airway and ventilation threats

›pH <7.25 with rising PaCO2 — severe acidemia, high risk of cardiovascular collapse

›Prepare for intubation or escalate NIV immediately

›Class I consensus recommendation for urgent airway intervention

›CO2 narcosis — confusion, somnolence, or coma

›Inability to protect airway mandates intubation

›NIV is contraindicated when airway protection is lost

›Respiratory rate <8 or >30 with accessory muscle use or abdominal paradox

›Impending respiratory arrest trigger

›Escalate to resuscitation bay

›Hemodynamic instability — hypotension unresponsive to initial fluid resuscitation

›SBP <90 mmHg or MAP <65 mmHg

›Mixed acidosis (coexistent metabolic acidemia) portends worse outcome

Monitoring and targets

›Monitoring bundle

›Continuous pulse oximetry

›Target SpO2 88-92% in known CO2 retainers

›Avoid high-flow O2 — blunts hypoxic drive in chronic hypercapnia

›Cardiac monitor

›Arrhythmia screen in severe acidemia (pH <7.1 — widened QRS, ventricular arrhythmias)

›Atrial fibrillation associated with worse outcomes in COPD exacerbation

›Arterial blood gas at 1-2 hours after NIV initiation

›Improvement in pH and PaCO2 expected within 1 hour of BiPAP

›Failure to improve is a trigger for intubation

›Repeat ABG to confirm acute vs. chronic vs. acute-on-chronic classification

›Acute: HCO3 rises 1 mmol/l per 10 mmHg rise in PaCO2

›Chronic: HCO3 rises 3.5-4 mmol/l per 10 mmHg rise in PaCO2

02History/hx62

Presenting symptoms

›Core respiratory symptoms

›Dyspnea

›Onset and tempo — acute (hours-days) vs. chronic (weeks-months)

›Exertional vs. rest symptoms

›Orthopnea and sleep-disordered breathing

›Snoring, witnessed apneas, morning headaches

›Daytime somnolence as OHS clue

›Cough and sputum

›Color, volume, change from baseline

Neurologic and systemic symptoms

›CNS symptoms of hypercapnia

›Morning headache — cerebral vasodilation from elevated PaCO2

›Characteristic of chronic hypercapnia or nocturnal hypoventilation

›May be only symptom in compensated state

›Somnolence, confusion, asterixis

›CO2 narcosis when PaCO2 acutely elevated >80 mmHg

›Escalation trigger regardless of pH

›Ankle edema

›Cor pulmonale in chronic respiratory acidosis

›Right heart failure from pulmonary hypertension

Risk factors and exposures

›Causative medication and substance exposures

›Opioids, benzodiazepines, barbiturates, general anesthetics

›Dose and timing of last exposure

›Polypharmacy combinations — synergistic CNS depression

›Excessive supplemental O2 in chronic CO2 retainers

›Worsening hypercapnia by blunting hypoxic drive

03Physical Exam/exam53

Vital signs

›Respiratory and hemodynamic stability

›Respiratory rate

›Tachypnea >24 in obstructive, >30 in restrictive disease

›Paradoxically low RR in CNS depression — opioid, sedative, brainstem event

›Tachycardia and blood pressure

›Hypertension from sympathetic activation by hypercapnia

›Hypotension in severe decompensation — late and ominous

›SpO2

›Does not reflect PaCO2 — normal SpO2 does not exclude hypercapnia

›Supplemental O2 may mask hypoventilation

Respiratory exam

›Work of breathing and airway

›Accessory muscle use

›Sternocleidomastoid and scalene recruitment

›Inability to speak in full sentences — escalation trigger

›Abdominal paradox

›Inward abdominal movement on inspiration — diaphragm fatigue

›High-risk sign for respiratory arrest

›Breath sounds

›Wheeze and prolonged expiration — obstructive pattern (COPD, asthma)

›Diminished breath sounds — air trapping, neuromuscular weakness, pneumothorax

Neurologic exam

›Hypercapnia neurologic signs

›Altered mental status

›Confusion or somnolence — CO2 narcosis

›Agitation may precede somnolence

›Asterixis

04Differential Diagnosis/ddx48

Life-threatening causes requiring immediate action

›CNS depression

›Opioid or sedative overdose

›ICD-10 T40.1 (opioid), T42.4 (benzodiazepine)

›Pinpoint pupils, low RR, response to naloxone

›Brainstem stroke or hemorrhage

›ICD-10 I61.3 brainstem hemorrhage, I63.3 cerebral infarction

›Focal neurologic signs, asymmetry, no drug exposure

›Myasthenic crisis

›ICD-10 G70.01

›Descending weakness, ptosis, diplopia, fatigue pattern

›Severe status asthmaticus

›ICD-10 J45.51

›Rising PaCO2 in asthma is an ominous late sign of fatigue

›Neuromuscular failure

›Guillain-Barre syndrome

›ICD-10 G61.0

›Ascending weakness, areflexia, recent infection or vaccination

›Urgent NIF — worse than -20 cmH2O triggers ICU

›ALS and muscular dystrophy

›Progressive bulbar and limb weakness

›Often acute-on-chronic presentation

Common chronic causes

›Chronic obstructive pulmonary disease

›ICD-10 J44.1 (COPD with exacerbation)

›Most common cause of chronic respiratory acidosis

›Compensated chronic hypercapnia with acute-on-chronic decompensation

›Obesity hypoventilation syndrome

05Laboratory Tests/lt48

Arterial and venous blood gas

›Arterial blood gas — gold standard for respiratory acidosis

›pH — defines severity

›Mild: pH 7.30-7.35

›Moderate: pH 7.25-7.30

›Severe: pH <7.25 — high NIV failure risk

›PaCO2 — primary derangement in respiratory acidosis

›Normal 35-45 mmHg

›Elevated above 45 mmHg confirms hypoventilation

›HCO3 and base excess — compensation assessment

›Acute: HCO3 rises 1 mmol/l per 10 mmHg rise in PaCO2

›Chronic: HCO3 rises 3.5-4 mmol/l per 10 mmHg rise in PaCO2

›A-a gradient calculation

›Normal A-a gradient — pure hypoventilation (CNS, neuromuscular, obesity)

›Elevated A-a gradient — intrinsic lung disease (COPD, pneumonia, pulmonary edema)

›Venous blood gas — reasonable screening tool

›Venous PCO2 typically 4-6 mmHg higher than arterial

›Cochrane 2025: VBG correlates with ABG and can rule out significant hypercarbia

›Use to assess trend; ABG preferred for precision titration

Core metabolic labs

›Basic metabolic panel

›Serum HCO3 — confirms compensation state

›Elevated in chronic respiratory acidosis

›Low (or normal) in acute respiratory acidosis

›Potassium

›Acidemia shifts K+ extracellularly — hyperkalemia risk

›Peaked T waves or widened QRS on ECG correlates

›BUN and creatinine

06Diagnostic Tests/dt67

Scoring Systems

›Acid-base severity classification

›pH-based severity stratification (Epstein and Singh, Respiratory Care 2001)

›Mild: pH 7.30-7.35, PaCO2 45-60 mmHg — may respond to medical therapy alone

›Moderate: pH 7.25-7.30, PaCO2 60-80 mmHg — strong indication for NIV

›Severe: pH <7.25 — high risk of NIV failure, prepare for intubation

›Acute vs. chronic vs. acute-on-chronic classification

›Acute: standard base excess 0 +/- 2 mEq/L (no renal compensation yet)

›Chronic: SBE = 0.4 x (PaCO2 - 40)

›Acute-on-chronic: compensation present but insufficient for degree of hypercapnia

›NIV failure risk stratification

›APACHE II score for ICU severity if applicable

›Higher scores correlate with NIV failure and intubation need

›Integrate with pH, mental status, and physiologic trajectory

›GBS disability scale for Guillain-Barre

›Score >= 3 or NIF worse than -20 cmH2O — ICU admission

›Score 0-2 — close monitoring with serial NIF

MRI

›MRI brain indications in respiratory acidosis

›Suspected brainstem lesion causing central hypoventilation

›Brainstem stroke not seen on CT (posterior fossa)

›Paraneoplastic encephalitis or demyelination

›MRI spine for high cervical cord lesion

›C3-C5 injury disrupts phrenic nerve — diaphragm paralysis

›Trauma or malignancy history

›Limitations in acute respiratory failure

›Requires patient cooperation and stability

›Motion artifact from labored breathing

07Disposition/dispo40

ICU admission criteria

›ICU indications

›Severe acidemia — pH <7.25

›High NIV failure risk

›Intubation preparation required

›NIV failure or contraindication

›Declining mental status on NIV

›Inability to protect airway

›Hemodynamic instability

›Vasopressor requirement

›Lactate >2 mmol/l with circulatory compromise

›Rapidly worsening trajectory despite initial therapy

›Rising PaCO2 on serial ABG

›Escalating oxygen requirement

Step-down and telemetry admission

›Intermediate care indications

›Moderate acidemia — pH 7.25-7.35 — improving on NIV

›Serial ABG showing pH trend toward normal

›PaCO2 declining with treatment

›New supplemental O2 requirement above baseline

›Stable vitals without vasopressor need

›Tolerating NIV without deterioration

›Arrhythmia concern

›New atrial fibrillation in COPD exacerbation

›Telemetry for monitoring

Observation and discharge

›Observation indications

›Mild respiratory acidosis responding fully to treatment

08Treatment/t94

Controlled oxygen therapy

›Oxygen titration in CO2 retainers

›Target SpO2 88-92% in known or suspected CO2 retainers

›Avoid high-flow O2 — suppresses hypoxic drive worsening hypercapnia

›Venturi mask preferred for precise FiO2 delivery (24-28%)

›SpO2 >92% target in patients without chronic hypercapnia

›Titrate to minimum O2 maintaining saturation

›Reassess with ABG if uncertain about CO2 retention baseline

Non-invasive ventilation

›BiPAP as first-line for acute hypercapnic respiratory failure

›Indications

›pH <7.35 and PaCO2 >45 mmHg with respiratory distress

›COPD exacerbation — Class I recommendation (Nava and Hill, Lancet 2009)

›OHS with acute decompensation

›Starting settings

›IPAP 10-12 cmH2O

›EPAP 4-5 cmH2O

›Titrate IPAP by 2 cmH2O increments to reduce work of breathing

›Response monitoring

›Repeat ABG at 1-2 hours

›Improvement in pH and PaCO2 expected

›Failure to improve by 1-2 hours — escalate to intubation

›Contraindications

›Cardiac or respiratory arrest

›Inability to protect airway

›Copious uncontrolled secretions

›Hemodynamic instability

›Facial trauma or recent upper airway surgery

Etiology-directed therapy

›COPD exacerbation

›Inhaled bronchodilators

›Albuterol 2.5 mg nebulized every 20 minutes x3, then every 1-4 hours

›Ipratropium 0.5 mg nebulized every 6-8 hours

›Systemic corticosteroids

›Prednisone 40 mg PO daily for 5 days (non-inferior to longer courses)

›Methylprednisolone 40-125 mg IV if unable to take PO

›Antibiotics when COPD exacerbation features suggest infection

›Azithromycin 500 mg PO/IV daily x5 days or doxycycline 100 mg PO twice daily x5-7 days

›Reserve broader coverage for hospitalized patients with severe exacerbation

›Opioid-induced hypoventilation

›Naloxone 0.4-2 mg IV bolus

›Repeat every 2-3 minutes as needed for response

›Titrate to spontaneous respirations, not full reversal (avoids acute withdrawal)

›Naloxone infusion if long-acting opioid ingested

›Two-thirds of effective bolus dose per hour

›Monitor for re-narcotization as naloxone wears off

›Benzodiazepine-induced hypoventilation

›Flumazenil 0.2 mg IV over 30 seconds

›Repeat 0.2 mg every 1 minute to maximum 1 mg

›Caution — seizure risk in benzodiazepine-dependent patients

›Short duration of action — observe for re-sedation

›Neuromuscular crisis (myasthenia gravis, Guillain-Barre)

›Urgent neurology consultation

›Plasmapheresis or IVIG for myasthenic crisis or severe GBS

›Pyridostigmine for myasthenic crisis — 30-60 mg PO every 4-8 hours

›NIF and vital capacity monitoring

›Intubate if NIF worse than -20 cmH2O or VC <15 mL/kg

›Elective intubation preferred over emergent

›Status asthmaticus with rising PaCO2

›Aggressive bronchodilators — albuterol continuous nebulization

›10-15 mg/hour continuous

›IV magnesium sulfate 2 g over 20 minutes — Class I recommendation

›Systemic corticosteroids

›Methylprednisolone 125 mg IV every 6 hours

›Transition to PO when clinical improvement achieved

›Ketamine for intubation in status asthmaticus

›1-2 mg/kg IV for RSI — bronchodilatory properties

›Preferred induction agent over propofol in bronchospasm

Invasive mechanical ventilation

›Intubation strategy in respiratory acidosis

›Rapid sequence intubation preparation

›Pre-oxygenate with NIV or high-flow NC — avoid bag-mask in active vomiting

›Ketamine 1-2 mg/kg IV or etomidate 0.3 mg/kg IV for induction

›Succinylcholine 1.5 mg/kg IV or rocuronium 1.2 mg/kg IV for paralysis

›Post-intubation ventilator targets in chronic hypercapnia

›Target baseline PaCO2 — not normal values

›Overcorrection risks posthypercapnic metabolic alkalosis

›Tidal volume 6-8 mL/kg IBW

›Permissive hypercapnia strategy in obstructive disease

›Allow PaCO2 up to 80 mmHg if pH >7.20 and hemodynamically stable

›Reduces barotrauma risk in severe air trapping

›PEEP 5-8 cmH2O to counterbalance intrinsic PEEP in COPD

Adjunct pharmacotherapy

›Acetazolamide

›Carbonic anhydrase inhibitor promoting renal HCO3 excretion

›Augments ventilatory drive in chronic compensated respiratory acidosis

›250-500 mg PO or IV twice daily

›Indications

›Posthypercapnic alkalosis after over-rapid correction

›Chronic OHS or COPD with disproportionate HCO3 elevation

›Cochrane 2001 (Jones and Greenstone) — limited RCT evidence but physiologically sound

›Sodium bicarbonate

›Not recommended for isolated respiratory acidosis

›No RCT evidence of benefit

›Risk of paradoxical intracellular acidosis and volume overload

›Chand et al. Curr Opin Nephrol Hypertens 2021 — use only in mixed respiratory plus metabolic acidosis with severe acidemia (pH <7.15)

›If used in mixed acidosis

›Sodium bicarbonate 1-2 mEq/kg IV over 30-60 minutes

›Re-check pH and PaCO2 within 30 minutes

09Special Populations/sp80

Pregnancy

›Physiologic considerations in pregnancy

›Baseline respiratory alkalosis in pregnancy

›Normal PaCO2 28-32 mmHg in third trimester

›PaCO2 >40 mmHg in a pregnant patient represents significant respiratory acidosis

›Diaphragm elevation from gravid uterus

›Reduced FRC — faster desaturation with apnea

›Greater risk of hypoventilation with sedation or obesity

›Aspiration risk increased

›Delayed gastric emptying and increased intraabdominal pressure

›Nil-by-mouth precautions critical before intubation

›Treatment modifications in pregnancy

›NIV safe in pregnancy for acute hypercapnic failure

›Monitor fetal heart rate when gestation >23 weeks

›Maintain maternal SpO2 >95% to ensure fetal oxygenation

›Intubation modifications

›Rapid sequence intubation preferred — full stomach risk

›Smaller ETT may be required (6.0-6.5 mm) due to airway edema

›Medication safety

›Naloxone safe in pregnancy — may precipitate fetal withdrawal

›Avoid benzodiazepines — neonatal respiratory depression

›Magnesium — caution with neuromuscular disease or renal impairment

›Fetal monitoring

›Continuous electronic fetal monitoring when viable gestation (>23-24 weeks)

›Obstetrics consultation for any severe maternal respiratory failure

Geriatric

›Age-related physiologic changes

›Reduced respiratory reserve

›Decreased muscle mass affects respiratory muscle strength

›Increased chest wall stiffness — higher work of breathing at baseline

›Blunted ventilatory response to hypercapnia

›Higher baseline PaCO2 in many older adults

›Slower compensation capacity

›Cognitive overlap

›Delirium as primary or concurrent presentation

›Dementia masking early hypercapnic confusion

›Clinical presentation differences

›Atypical presentation common

›Afebrile infection triggering COPD exacerbation

›Lethargy or withdrawal rather than dyspnea complaint

›Polypharmacy — opioid and sedative sensitivity

›Lower doses cause respiratory depression

›Review medication list for contributing agents

›Management modifications

›NIV tolerance may be reduced

›Claustrophobia, delirium, or inability to cooperate with mask

›High-flow nasal cannula (HFNC) as bridge or alternative

›Renal dosing — reduced clearance affects drug levels

›Naloxone may need smaller initial doses

›Acetazolamide — reduce dose if GFR <30 mL/min/1.73m2

›Disposition bias toward ICU or monitored bed

›Frailty and limited reserve increase deterioration risk

›Limited home support for new home NIV

Pediatrics

›Age-specific normal values

›Respiratory rate age-dependent

›Neonates: 40-60 breaths/min

›Infants: 30-60 breaths/min

›Children 6-12 years: 18-30 breaths/min

›PaCO2 normal range similar to adults (35-45 mmHg)

›Neonates may tolerate permissive hypercapnia in lung protective strategies

›Any PaCO2 >50 mmHg with acidemia warrants urgent evaluation

›Common pediatric etiologies

›Bronchiolitis — infants

›RSV most common; rising PaCO2 signals impending failure

›High-flow nasal cannula first-line escalation

›Severe asthma

›Rising PaCO2 is late and ominous — indicates respiratory muscle fatigue

›Heliox (70/30 helium-oxygen) may reduce work of breathing

›Neuromuscular disease

›Spinal muscular atrophy (SMA) — respiratory failure often first manifestation

›Duchenne muscular dystrophy — scoliosis worsens restrictive physiology

›Management in pediatrics

›NIV in children

›BiPAP well-tolerated in school-age children with appropriate interface

›IPAP 10-12 cmH2O, EPAP 4-5 cmH2O — similar starting points to adults

›Medication dosing

›Naloxone 0.01 mg/kg IV (maximum 0.4 mg per dose) — titrate to respirations

›Albuterol 0.15 mg/kg (minimum 2.5 mg) nebulized every 20 minutes x3 in asthma

›Methylprednisolone 1-2 mg/kg IV (maximum 125 mg) for asthma or COPD-equivalent

›Intubation parameters

›ETT size uncuffed: age/4 + 4; cuffed: age/4 + 3.5

›Tidal volume target 6 mL/kg IBW in lung protective ventilation

10Background/b89

Epidemiology

›Incidence and population burden

›COPD — most common cause of chronic respiratory acidosis

›COPD affects approximately 10% of adults over 40 worldwide

›Acute exacerbations leading to hypercapnic respiratory failure account for significant ED and ICU utilization

›Opioid overdose — major acute cause in younger populations

›Opioid-related respiratory depression — leading cause of overdose death

›Rising incidence with synthetic opioids (fentanyl, carfentanil)

›Obesity hypoventilation syndrome

›Prevalence 10-20% in patients with BMI >40 kg/m2

›Frequently underdiagnosed — daytime hypercapnia without recognized diagnosis

›Neuromuscular disease

›ALS — median survival 2-4 years with respiratory failure as leading cause of death

›GBS — annual incidence 1-2 per 100,000; 25% require mechanical ventilation

›Outcomes and mortality

›In-hospital mortality for hypercapnic COPD exacerbation with acidemia

›pH <7.25 — mortality up to 30-40% even with NIV

›NIV reduces intubation rate by 65% and mortality by 46% vs. standard therapy (Nava and Hill, Lancet 2009)

›Prognosis dependent on rapidity of correction and underlying etiology reversibility

›Reversible causes (opioid, postoperative) — excellent prognosis with treatment

›Progressive neuromuscular disease — chronic course requiring long-term NIV

Pathophysiology

›Mechanism of CO2 accumulation

›Alveolar hypoventilation — primary mechanism in all respiratory acidosis

›Minute ventilation insufficient to eliminate CO2 produced by metabolism

›CO2 production increases with high-carbohydrate diet (respiratory quotient ~1.0 vs ~0.7 for fat)

›V/Q mismatch contribution

›Dead space ventilation — air moves in and out but no gas exchange

›Severe V/Q mismatch may require extremely high minute ventilation to compensate

›Increased CO2 production

›Fever, agitation, seizures, heavy work of breathing

›Sepsis and hypermetabolic states

›Compensation mechanisms

›Acute compensation (minutes to hours)

›Intracellular buffering by hemoglobin and proteins

›HCO3 rises minimally — 1 mmol/l per 10 mmHg rise in PaCO2

›Chronic compensation (3-5 days)

›Renal HCO3 retention via increased tubular H+ excretion

›HCO3 rises 3.5-4 mmol/l per 10 mmHg rise in PaCO2

›Full renal compensation takes 3-5 days

›Posthypercapnic alkalosis

›Occurs when CO2 corrected faster than kidneys can excrete retained HCO3

›Results in metabolic alkalosis after resolution of respiratory acidosis

›Systemic effects of hypercapnia

›Cerebrovascular effects

›CO2 is a potent cerebral vasodilator — increased CBF and ICP

›Papilledema and headache from increased intracranial pressure

›Cardiovascular effects

›Peripheral vasodilation — bounding pulses, flushed skin

›Sympathetic activation — tachycardia, hypertension initially

›Myocardial depression in severe acidemia (pH <7.1) — bradycardia, reduced contractility

›Electrolyte effects

›Acidemia shifts K+ out of cells — hyperkalemia risk

›Risk of arrhythmia worsens with hyperkalemia

Therapeutic Considerations

›NIV evidence base

›BiPAP in hypercapnic COPD exacerbation

›Class I recommendation — reduces intubation rate and in-hospital mortality

›Number needed to treat approximately 8 to prevent one intubation

›Bourke et al. Lancet Respir Med 2018 — extending NIV benefits beyond guidelines

›Helmet vs. oronasal mask interface

›Helmet better tolerated for prolonged use

›Oronasal mask faster setup in acute emergency

›NIV failure predictors

›pH <7.25 at initiation

›APACHE II score >29

›Failure to improve pH within 1-2 hours

›Bicarbonate controversy

›Sodium bicarbonate not recommended for isolated respiratory acidosis

›Adrogué and Madias, AJKD 2020 — paradoxical intracellular acidosis from CO2 generation

›Chand et al. Curr Opin Nephrol Hypertens 2021 — no RCT evidence of mortality benefit

›May worsen hypercapnia by generating additional CO2

›Narrow indications if used

›Mixed respiratory plus metabolic acidosis with pH <7.15

›Only if ventilation can be provided to blow off CO2 generated

›Permissive hypercapnia in mechanical ventilation

›Deliberate acceptance of elevated PaCO2 to limit ventilator-induced lung injury

›Targets PaCO2 50-80 mmHg with pH >7.20

›Most evidence in ARDS and severe asthma

›Avoid rapid normalization in chronic hypercapnia

›Target patient's baseline PaCO2

›Rapid correction risks posthypercapnic alkalosis and seizure

›Long-term management principles

›Home NIV — nocturnal BiPAP reduces chronic hypercapnia in OHS and COPD

›Improves survival in OHS with chronic hypercapnic respiratory failure

›Adherence monitoring required

›Pulmonary rehabilitation in COPD

›Reduces exacerbation frequency and severity

›Improves respiratory muscle conditioning

›Weight management in OHS

›Weight loss of 10-15% significantly improves OHS and sleep apnea

›Bariatric surgery may resolve OHS in eligible patients

11Patient Discharge Instructions/pdi42

copy discharge instructions

›Respiratory acidosis home care instructions

›Take all prescribed medications exactly as directed

›Inhalers, oral steroids, antibiotics — complete the full course

›Do not skip doses of home BiPAP or CPAP

›Use your breathing machine (BiPAP/CPAP) every night without exception

›Skipping your machine raises CO2 and can cause dangerous sleepiness

›Keep mask clean and replace as recommended

›Avoid anything that slows your breathing

›No alcohol, sleeping pills, or sedatives unless prescribed by your doctor

›Tell any doctor or dentist about your breathing condition before receiving sedatives

›Oxygen use — if prescribed, use exactly as prescribed

›Do not increase your flow rate without doctor guidance

›Too much oxygen can raise your CO2 and make you drowsy

›Diet guidance

›High-fat, lower-carbohydrate meals produce less CO2 — may ease breathing

›Stay well hydrated to help clear secretions

›Weight management is important if obesity is contributing

›Warning signs — return to ER immediately

›Difficulty breathing at rest or waking from sleep gasping

›Unable to speak a full sentence without stopping to breathe

›Breathing much faster or slower than usual

›Increased confusion, unusual sleepiness, or very difficult to wake up

›These are signs of CO2 building up — dangerous and urgent

›Call 911 — do not drive yourself

›Blue or grey lips, fingernails, or face

›Sign of very low oxygen

›Call 911 immediately

12References/r28

Guidelines and key sources

›Key clinical guidelines

›ACEP Expert Panel 2025 — Baugh CW et al., Acute Care of Patients With Moderate Respiratory Distress, Western J Emerg Med 2025

›Recommendations for NIV use and escalation in ED

›Nava S and Hill N — Non-Invasive Ventilation in Acute Respiratory Failure, Lancet 2009

›Class I NIV recommendation for acute hypercapnic respiratory failure

›NIV reduces intubation rate by 65% and mortality by 46% vs. standard therapy

›Bourke SC et al. — Beyond the Guidelines for NIV in Acute Respiratory Failure, Lancet Respir Med 2018

›Extended NIV applications and failure predictors

›Adrogué HJ and Madias NE — Management of Life-Threatening Acid-Base Disorders, NEJM 1998

›NIV contraindications and intubation thresholds

Core references

›Primary evidence sources

›Epstein SK and Singh N — Respiratory Acidosis, Respiratory Care 2001

›Classification of acute, chronic, and acute-on-chronic respiratory acidosis

›HCO3 compensation rules: acute 1 mmol/l per 10 mmHg; chronic 3.5-4 mmol/l per 10 mmHg

›Palmer BF and Clegg DJ — Respiratory Acidosis and Respiratory Alkalosis Core Curriculum 2023, AJKD 2023

›Epidemiology, compensation mechanisms, and pathophysiology

›Berend K et al. — Physiological Approach to Assessment of Acid-Base Disturbances, NEJM 2014

›Systematic acid-base interpretation framework

›Chand R, Swenson ER, Goldfarb DS — Sodium Bicarbonate Therapy for Acute Respiratory Acidosis, Curr Opin Nephrol Hypertens 2021

›Evidence against bicarbonate in isolated respiratory acidosis

›Adrogué HJ and Madias NE — Alkali Therapy for Respiratory Acidosis: A Medical Controversy, AJKD 2020

›Paradoxical CO2 generation and intracellular acidosis risk

›Byrne AL et al. — Peripheral Venous Blood Gas Analysis, Cochrane Database 2025

›VBG correlation with ABG for hypercarbia assessment

›Jones PW and Greenstone M — Carbonic Anhydrase Inhibitors for Hypercapnic Ventilatory Failure in COPD, Cochrane 2001

›Acetazolamide evidence base in chronic compensated respiratory acidosis

Learn More: Respiratory Acidosis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.